Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1999

View Archived Issues

New approach to inhibiting thrombin-induced neuronal cell death

Vagus nerve stimulation offers new possibilities for the treatment of depression

Preliminary results reported for Biojector 2000-delivered malaria vaccine

Biomira's BLP25 liposome technology offers promise as cancer therapy

MGH team identifies TSP-2 as a novel endogenous antiangiogenic factor

Immune Network Research reacquires 1F7 AIDS antibody

Genome Therapeutics initiates osteoporosis genomics alliance with Wyeth-Ayerst

Millennium validates prostate cancer gene target as part of Lilly collaboration

NPS and Allelix finalize merger

Nycomed Amersham files for E.U. approval of ultrasound imaging agent

Schwarz adds new anticonvulsant to R&D portfolio

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Cel-Sci completes another study in head and neck cancer

BIM-46068: a pseudopeptide FTase inhibitor with promise for cancer Rx

Interneuron licenses worldwide rights to pagoclone to Warner-Lambert

Salix responds to FDA approvable letter and reacquires rights to UC treatment from AstraZeneca

Agents for accelerating peristalsis in development at Dainippon

New series of selectin inhibitors patented by Sumitomo

Mitsui presents differentiation-inducing agents

ADIR discloses new melatonergic agents with cyclic structure

Antiangiogenic fumagillin analogues in the pipeline at BioChem Pharma

BMS presents new water-soluble triazole antifungal prodrugs with superior properties

Pharmacological profile of SR-141716A, a selective CB1 antagonist, further characterized

Citicoline Stroke Study Group trial does not show benefit for citicoline in overall study population

Aventis receives first product approval: E.U. grants approval of Synercid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...